DDInter458 DDInter824
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. In combination with , glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. It demonstrates a high genetic barrier against resistance mutations of the virus. In cell cultures, the emergence of amino acid substitutions at NS3 resistance-associated positions A156 or D/Q168 in HCV genotype 1a, 2a or 3a replicons led to reduced susceptibility to glecaprevir [FDA Label]. The combinations of amino acid substitutions at NS3 position Y65H and D/Q168 also results in greater reductions in glecaprevir susceptibility, and NS3 Q80R in genotype 3a patients also leads to glecaprevir resistance [FDA Label]. Glecaprevir is available as an oral combination therapy with under the brand name Mavyret. This fixed-dose combination therapy was FDA-approved in August 2017 to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis . Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both . Hepatitis C viral infection often leads to decreased liver function and subsequent liver failure, causing a significantly negative impact on the patients' quality of life. The ultimate goal of the combination treatment is to achieve sustained virologic response (SVR) and cure the patients from the infection. In clinical trials, this combination therapy achieved SVR12 rate, or undetectable Hepatitis C for twelve or more weeks after the end of treatment, of ≥93% across genotypes 1a, 2a, 3a, 4, 5 and 6 [FDA Label].
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Griseofulvin
Griseofulvin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glecaprevir
Cyclosporine {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Griseofulvin
Griseofulvin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glecaprevir
Cyclosporine {u} (Compound) causes {v} (Side Effect) Neuropathy peripheral
Neuropathy peripheral {u} (Side Effect) is caused by {v} (Compound) Griseofulvin
Griseofulvin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glecaprevir
Cyclosporine {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Simvastatin
Simvastatin {u} may lead to a major life threatening interaction when taken with {v} Glecaprevir
Cyclosporine {u} (Compound) causes {v} (Side Effect) Neuropathy peripheral
Neuropathy peripheral {u} (Side Effect) is caused by {v} (Compound) Simvastatin
Simvastatin {u} may lead to a major life threatening interaction when taken with {v} Glecaprevir
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Simvastatin
Simvastatin {u} may lead to a major life threatening interaction when taken with {v} Glecaprevir
Cyclosporine {u} (Compound) downregulates {v} (Gene) CDK2
CDK2 {u} (Gene) is bound by {v} (Compound) Bosutinib
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glecaprevir
Cyclosporine {u} (Compound) downregulates {v} (Gene) PSRC1
PSRC1 {u} (Gene) is upregulated by {v} (Compound) Bosutinib
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glecaprevir
Cyclosporine {u} (Compound) upregulates {v} (Gene) INSIG1
INSIG1 {u} (Gene) is upregulated by {v} (Compound) Bosutinib
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glecaprevir
Cyclosporine {u} (Compound) upregulates {v} (Gene) INSIG1
INSIG1 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glecaprevir
Cyclosporine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Griseofulvin (Compound) and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir
Cyclosporine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Griseofulvin (Compound) and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir
Cyclosporine (Compound) causes Neuropathy peripheral (Side Effect) and Neuropathy peripheral (Side Effect) is caused by Griseofulvin (Compound) and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir
Cyclosporine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Simvastatin (Compound) and Simvastatin may lead to a major life threatening interaction when taken with Glecaprevir
Cyclosporine (Compound) causes Neuropathy peripheral (Side Effect) and Neuropathy peripheral (Side Effect) is caused by Simvastatin (Compound) and Simvastatin may lead to a major life threatening interaction when taken with Glecaprevir
Cyclosporine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Simvastatin (Compound) and Simvastatin may lead to a major life threatening interaction when taken with Glecaprevir
Cyclosporine (Compound) downregulates CDK2 (Gene) and CDK2 (Gene) is bound by Bosutinib (Compound) and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir
Cyclosporine (Compound) downregulates PSRC1 (Gene) and PSRC1 (Gene) is upregulated by Bosutinib (Compound) and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir
Cyclosporine (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is upregulated by Bosutinib (Compound) and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir
Cyclosporine (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is downregulated by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir